Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.

3 years ago

Franchise includes AMZEEQ® for the treatment of acne and ZILXI® for the treatment of rosacea, and a development-stage dermatology program…

Tiziana Life Sciences Announces Death of Director

3 years ago

NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies…

VYNE Therapeutics Divests Topical Minocycline Assets

3 years ago

Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE’s strategic…

Acutus Medical’s Pulsed Field Ablation System To Be Featured During 27th Annual AF Symposium

3 years ago

CARLSBAD, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on…

Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea

3 years ago

MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on…

Global Wholehealth Partners Corporation Declares Special Common Stock Dividend

3 years ago

San Clemente, CA, Jan. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- On January 13, 2022, Global Wholehealth Partners Corporation…

Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

3 years ago

Clinical trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration…

Settlement Reached in Tietz Class Action Lawsuit

3 years ago

Vancouver, British Columbia--(Newsfile Corp. - January 13, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"),…

Halberd, Corp. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases

3 years ago

Jackson Center, Pennsylvania--(Newsfile Corp. - January 13, 2022) - Halberd, Corp. (OTC PINK: HALB) ("HALB" or the "Company"), an innovative…